Reactivation of Plasmodium infection during a treatment with infliximab: A case report

C Haeseleer; D Martiny; Y Van Laethem; B Cantinieaux; C Martin

doi:10.1016/j.ijid.2019.11.016

Reactivation of Plasmodium infection during a treatment with infliximab: A case report

Int J Infect Dis. 2020 Feb:91:101-103. doi: 10.1016/j.ijid.2019.11.016. Epub 2019 Nov 20.

Authors

C Haeseleer¹, D Martiny², Y Van Laethem³, B Cantinieaux⁴, C Martin³

Affiliations

¹ Department of Hematology, Laboratoire Hospitalier Universitaire de Bruxelles - Universitair Laboratorium Brussel (LHUB-ULB), Brussels, Belgium; Université Libre de Bruxelles, Brussels, Belgium. Electronic address: cecile.haeseleer@lhub-ulb.be.
² Department of Microbiology, Laboratoire Hospitalier Universitaire de Bruxelles - Universitair Laboratorium Brussel (LHUB-ULB), Brussels, Belgium; Faculté de Médecine et Pharmacie, Université de Mons (UMONS), Mons, Belgium.
³ Department of Infectious Diseases, Centre Hospitalier Universitaire Saint- Pierre, Université Libre de Bruxelles, Brussels, Belgium.
⁴ Department of Hematology, Laboratoire Hospitalier Universitaire de Bruxelles - Universitair Laboratorium Brussel (LHUB-ULB), Brussels, Belgium.

PMID: 31759170
DOI: 10.1016/j.ijid.2019.11.016

Abstract

We describe a symptomatic Plasmodium falciparum infection in a 29-year-old Guinean man receiving Infliximab for one year and without recent travel. The reactivation of submicroscopic malaria following the inhibition of TNF-alpha by infliximab is suspected.

Keywords: Infliximab; Low parasitemia; Malaria; Non-endemic areas; Reactivation.

Publication types

Case Reports

MeSH terms

Adult
Humans
Inflammatory Bowel Diseases / complications
Inflammatory Bowel Diseases / drug therapy
Infliximab / adverse effects*
Infliximab / therapeutic use
Malaria, Falciparum / etiology*
Male
Plasmodium falciparum
Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

Tumor Necrosis Factor-alpha
Infliximab